Argus analyst David Toung upgraded Integra LifeSciences (IART) to Buy from Hold with a $28 price target The firm sees the company as well-positioned for a turnaround, and with supply issues for Integra Skin products resolved, the company now expects sequentially stronger top and bottom-line growth as 2025 progresses. Argus also expects that under the leadership of new CEO Mojdeh Poul, the company will improve operations and sales execution in order tot meet demand for its reconstructive and neurosurgery products.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences upgraded to Buy from Hold at Argus
- Integra LifeSciences Reports Mixed Earnings Amid Challenges
- Sell Rating on Integra Lifesciences Amidst Uncertain Growth and Leadership Transition
- Integra Lifesciences Faces Supply Chain Challenges and Conservative Outlook, Leading to Sell Rating
- Optimistic Growth Outlook for Integra LifeSciences Amidst Transitional Phase and Strategic Initiatives